Skip to main content
. 2021 Aug 17;111(2):125–140. doi: 10.1007/s00392-021-01920-0

Fig. 4.

Fig. 4

Risk of acute cellular rejection in patients who underwent HTx due to CS versus other HF etiologies after 1 and 5 years of follow-up